Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme Moyle

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
The Journal of Infectious Diseases|March 28, 2013
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 resultsJoel E Gallant, Ellen Koenig, Jaime Andrade-Villanueva, et al.
AIDS (London, England)|November 8, 2017
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular riskJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
The Lancet. HIV|February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trialGraeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
European Journal of Pain (London, England)|March 12, 2021
Feasibility randomized-controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN studyWhitney Scott, Beth J Guildford, James Badenoch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
The Lancet. Infectious Diseases|February 15, 2014
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trialRichard B Pollard, Jürgen K Rockstroh, Giuseppe Pantaleo, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
The Journal of Infectious Diseases|March 28, 2013
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 resultsJoel E Gallant, Ellen Koenig, Jaime Andrade-Villanueva, et al.
AIDS (London, England)|November 8, 2017
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular riskJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
The Lancet. HIV|February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trialGraeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
European Journal of Pain (London, England)|March 12, 2021
Feasibility randomized-controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN studyWhitney Scott, Beth J Guildford, James Badenoch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
The Lancet. Infectious Diseases|February 15, 2014
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trialRichard B Pollard, Jürgen K Rockstroh, Giuseppe Pantaleo, et al.
Pageof 12